Key statistics
On Tuesday, Aquestive Therapeutics Inc (AQST:NMQ) closed at 4.92, -21.11% below its 52-week high of 6.23, set on Mar 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.87 |
---|---|
High | 5.10 |
Low | 4.86 |
Bid | 4.92 |
Offer | 5.00 |
Previous close | 4.85 |
Average volume | 1.34m |
---|---|
Shares outstanding | 91.06m |
Free float | 86.49m |
P/E (TTM) | -- |
Market cap | 447.56m USD |
EPS (TTM) | -0.3565 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 21:00 BST.
More ▼
Announcements
- Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
- Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
- Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
- Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™
- Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study
- Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET
- Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
- Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film
- Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024
More ▼